Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Blinatumomab in Pediatric R/R and MRD+ B-ALL
NCT07134088Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2025
- Primary completion
- Mar 2031
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Started Dec 2025; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07134088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134088.